<DOC>
	<DOCNO>NCT02926690</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) OTS167 administer via oral capsule ( PO ) patient relapsed/refractory locally advanced metastatic breast cancer .</brief_summary>
	<brief_title>Safety Efficacy Study MELK Inhibitor Treat Patients With Advanced Breast Cancer Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Dose Escalation Dose Expansion Cohorts Patients must meet follow criterion eligible participation study : 1 . Female patient , ≥ 18 year age time obtain informed consent . 2 . Patients document ( histologically cytologicallyproven ) breast cancer locally advance metastatic . 3 . Patients malignancy either relapsed/refractory standard therapy standard therapy available . 4 . Patients malignancy currently amenable surgical intervention due either medical contraindication nonresectability tumor . 5 . Patients measurable nonmeasurable disease accord Response Evaluation Criteria In Solid Tumor ( RECIST , v1.1 ) . 6 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 ( see APPENDIX B : Performance Status Evaluation ) . 7 . Life expectancy great equal 3 month . 8 . Resolution chemotherapyrelated radiationrelated toxicity Grade 1 severity low , except stable sensory neuropathy ( less equal Grade 2 ) . 9 . Patients either childbearing potential agree use medically effective method contraception study 3 month last dose study drug . ( See Appendix H : Forms contraception ) . 10 . Patients ability understand give write informed consent participation trial , include evaluation procedure specify protocol . Dose expansion Cohort TNBC 1 . Patients condition follow : ER &lt; 10 % , PR &lt; 10 % IHC assay ; And HER2 negative base ASCO CAP guideline 2 . Patients measurable disease accord response evaluation criterion TNBC ( RECIST , v1.1 ) 3 . Patients measurable disease easily access biopsy . 4 . Relapsed ( recurrence disease progression achieve document clinical response first secondline treatment ) refractory ( disease progression receive first line second line treatment ) . In case TNBC , prior initial therapy least one know active regimen TNBC include , limited , combination anthracyclines , taxanes , platinum agent , Ixabepilone , and/or cyclophosphamide require . Dose Escalation Dose Expansion Cohorts Patients meeting follow criterion ineligible participation study . 1 . Women pregnant lactating . Women childbearing potential ( WOCBP ) use adequate birth control see Appendix H : Forms contraception . 2 . Patients known central nervous system ( CNS ) leptomeningeal metastasis control prior surgery , radiotherapy require corticosteroid control symptom , patient symptoms suggest CNS involvement treatment require . 3 . Patients primary brain tumor . 4 . Patients hematologic malignancy . This include leukemia ( form ) , lymphoma , multiple myeloma . 5 . Patients follow hematologic abnormality baseline . ( Patients may receive red blood cell product transfusion prior study , clinically warrant . ) : Absolute neutrophil count ( ANC ) &lt; 1,500 per mm3 Platelet count &lt; 100,000 per mm3 Hemoglobin &lt; 8.0 gm/dL 6 . Patients follow serum chemistry abnormality baseline : Total bilirubin ≥ 1.5 × ULN institution value AST ALT ≥ 3 × ULN institution value ( ≥ 5 × due hepatic involvement tumor ) Creatinine ≥ 1.5 × ULN institution value ( calculated creatinine clearance &lt; 60 mL/min/1.73 m2* ) 7 . Patients significant active cardiovascular disease condition , include : Congestive heart failure ( CHF ) require therapy Need antiarrhythmic medical therapy ventricular arrhythmia Severe conduction disturbance Unstable angina pectoris require therapy QTc interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) QTc interval ≤ 300 msec History congenital long QT syndrome congenital short QT syndrome LVEF &lt; 50 % measure echocardiography MUGA scan Uncontrolled hypertension ( per Investigator 's discretion ) Class III IV cardiovascular disease accord New York Heart Association 's ( NYHA ) Functional Criteria ( see APPENDIX C : New York Heart Association 's Functional Criteria ) . Myocardial infarction ( MI ) within 6 month prior first study drug administration 8 . Patients know suspected hypersensitivity component OTS167 . 9 . Patients known history human immunodeficiency virus ( HIV ) active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 10 . Patients serious/active/uncontrolled infection , infection require parenteral antibiotic , unexplained fever &gt; 38ºC within 1 week prior first study drug administration . 11 . Patients inadequate recovery prior surgical procedure , patient undergo major surgical procedure within 4 week prior first study drug administration . 12 . Patients lifethreatening illness , significant organ system dysfunction , clinically significant laboratory abnormality , , opinion Investigator , would either compromise patient 's safety interfere evaluation safety study drug . 13 . Patients psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study . 14 . Patients inability foreseeable incapacity , opinion Investigator , comply protocol requirement . 15 . Any antineoplastic agent monoclonal antibody therapy primary malignancy ( standard experimental ) within 2 week prior first study drug administration . 16 . Radiotherapy wide field radiation within 4 week radiotherapy limited field radiation palliation within 1 week first dose study treatment . If acute symptom radiation fully resolve , extent timing radiotherapy eligibility discuss Investigator Sponsor . 17 . Patients require surgery primary metastatic primary malignancy . 18 . Herbal preparation relate counter ( OTC ) preparations/supplements contain herbal ingredient within 1 week prior first study drug administration study . 19 . Systemic hormonal therapy relate breast cancer treatment ( standard experimental ) within 1 week prior first study drug administration study . The following therapy allow : Hormonal therapy ( e.g. , Megace ) appetite stimulation Nasal , ophthalmic , inhaled , topical glucocorticoid preparation Oral replacement glucocorticoid therapy adrenal insufficiency Lowdose maintenance steroid therapy condition ( exclude steroid taper brain edema/metastases/radiation ) Hormonal contraceptive therapy ( WOCBP must combine nonhormonal contraceptive equivalent doublebarrier method ) 20 . Any investigational treatment study . This include participation medical device therapeutic intervention clinical trial . Dose expansion Cohort TNBC 21 . Patients lesion access biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>